Voraxaze

Active Ingredient(s): Glucarpidase
FDA Approved: * January 17, 2012
Pharm Company: * BTG INTERNATIONAL INC
Category: Antidotes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Voraxaze Overview

Some, but not all, carboxypeptidases are initially produced in an inactive form; this precursor form is referred to as a procarboxypeptidase. In the case of pancreatic carboxypeptidase A, the inactive zymogen form - pro-carboxypeptidase A - is converted to its active form - carboxypeptidase A - by the enzyme trypsin. This mechanism ensures that the cells wherein pro-carboxypeptidase A is produced are not themselves digested. See also Carboxypeptidase E Carboxypeptidase A Enzyme category ...

Read more Voraxaze Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Carboxypeptidase

Recent Voraxaze Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Glucarpidase
  • Injection: 1000 units per vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Voraxaze: (1 result)

Sorted by National Drug Code
  • 50633-210 Voraxaze 1000 [usp'u]/1 Intravenous Injection, Powder, for Solution by Btg International Inc.

Other drugs which contain Glucarpidase or a similar ingredient: (1 result)